These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 11861263)

  • 1. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
    Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
    Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
    Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
    Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
    Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
    Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
    Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW; Young HA; Pennington RW; Weeks SD
    Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
    Yi Q; Szmania S; Freeman J; Qian J; Rosen NA; Viswamitra S; Cottler-Fox M; Barlogie B; Tricot G; van Rhee F
    Br J Haematol; 2010 Sep; 150(5):554-64. PubMed ID: 20618329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
    Lim SH; Bailey-Wood R
    Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
    Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
    Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
    Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
    Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
    J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.
    Kafi K; Betting DJ; Yamada RE; Bacica M; Steward KK; Timmerman JM
    Mol Immunol; 2009 Jan; 46(3):448-56. PubMed ID: 19046770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
    Levy R; Ganjoo KN; Leonard JP; Vose JM; Flinn IW; Ambinder RF; Connors JM; Berinstein NL; Belch AR; Bartlett NL; Nichols C; Emmanouilides CE; Timmerman JM; Gregory SA; Link BK; Inwards DJ; Freedman AS; Matous JV; Robertson MJ; Kunkel LA; Ingolia DE; Gentles AJ; Liu CL; Tibshirani R; Alizadeh AA; Denney DW
    J Clin Oncol; 2014 Jun; 32(17):1797-803. PubMed ID: 24799467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.
    Cohen S; Haimovich J; Hollander N
    J Immunother; 2005; 28(5):461-6. PubMed ID: 16113602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
    Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
    J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
    Redfern CH; Guthrie TH; Bessudo A; Densmore JJ; Holman PR; Janakiraman N; Leonard JP; Levy RL; Just RG; Smith MR; Rosenfelt FP; Wiernik PH; Carter WD; Gold DP; Melink TJ; Gutheil JC; Bender JF
    J Clin Oncol; 2006 Jul; 24(19):3107-12. PubMed ID: 16754937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.